AR037592A1 - Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno - Google Patents

Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno

Info

Publication number
AR037592A1
AR037592A1 ARP020104591A ARP020104591A AR037592A1 AR 037592 A1 AR037592 A1 AR 037592A1 AR P020104591 A ARP020104591 A AR P020104591A AR P020104591 A ARP020104591 A AR P020104591A AR 037592 A1 AR037592 A1 AR 037592A1
Authority
AR
Argentina
Prior art keywords
hexadeca
triazatetraciclo
pentaeno
abbreviated
pharmaceutical formulations
Prior art date
Application number
ARP020104591A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR037592A1 publication Critical patent/AR037592A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formas de dosificación farmacéuticas orales de liberación controlada (abreviadamente LC) de 5, 8, 14-triazatetra-ciclo [10.3.1.0 2,11.04,9 ]-hexadeca-2(11), 3, 5, 7, 9-pentaeno, véase 1, y a las sales farmacéuticamente aceptables del mismo, y procedimientos en los que se usan para reducir la adicción a la nicotina o ayudar en el cese o reducción del uso del tabaco en tanto que reducen las náuseas como efecto adverso. Una composición de dosificación baja de liberación inmediata (abreviadamente LI) que poseen una formulación estable con una distribución y potencia del fármaco uniformes.
ARP020104591A 2001-11-30 2002-11-28 Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno AR037592A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33465201P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
AR037592A1 true AR037592A1 (es) 2004-11-17

Family

ID=23308160

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104591A AR037592A1 (es) 2001-11-30 2002-11-28 Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno

Country Status (31)

Country Link
US (1) US7771748B2 (es)
EP (1) EP1448235B1 (es)
JP (2) JP2005528330A (es)
KR (2) KR100892517B1 (es)
CN (2) CN1864663A (es)
AR (1) AR037592A1 (es)
AT (1) ATE356625T1 (es)
AU (1) AU2002351008B2 (es)
BR (1) BR0214806A (es)
CA (1) CA2467490C (es)
DE (1) DE60218885T2 (es)
DK (1) DK1448235T3 (es)
ES (1) ES2282492T3 (es)
GT (1) GT200200247A (es)
IL (1) IL161857A0 (es)
MX (1) MXPA04003807A (es)
MY (1) MY130619A (es)
NO (1) NO20042739L (es)
NZ (1) NZ532435A (es)
PA (1) PA8559501A1 (es)
PE (1) PE20040121A1 (es)
PL (1) PL208080B1 (es)
PT (1) PT1448235E (es)
PY (1) PY0228832A (es)
RU (2) RU2272629C2 (es)
SI (1) SI1448235T1 (es)
SV (1) SV2004001418A (es)
TW (1) TWI327471B (es)
UY (1) UY27553A1 (es)
WO (1) WO2003045437A1 (es)
ZA (1) ZA200403068B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1044189E (pt) * 1997-12-31 2008-04-22 Pfizer Prod Inc Compostos azapolicíclicos condensados com arilo
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
MXPA04003807A (es) 2001-11-30 2004-07-30 Pfizer Prod Inc Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno.
DK1803443T3 (en) * 2002-12-20 2019-02-25 Niconovum Ab Nicotine-containing particulate material with a crystalline cellulose
EP1633358A1 (en) * 2003-05-20 2006-03-15 Pfizer Products Inc. Pharmaceutical compositions of varenicline
US7051606B2 (en) * 2004-01-30 2006-05-30 Andrx Labs Llc Dosage form holder device and methods for immersion testing
WO2006040680A1 (en) * 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
CA2593432A1 (en) * 2005-01-07 2006-07-13 Prizer Products Inc. Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
US20110086086A1 (en) * 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
ZA200802602B (en) * 2005-08-24 2009-10-28 Rubicon Res Pvt Ltd Controlled release formulation
CA2646942C (en) 2006-03-16 2014-07-29 Modoral Brands Inc. Improved snuff composition
CN101420939A (zh) * 2006-04-24 2009-04-29 辉瑞产品公司 用于药物递送装置的不对称膜
US20090130206A1 (en) * 2006-05-09 2009-05-21 Umesh Nandkumar Khatavkar Controlled Release Compositions of an Antidepressant Agent
US20080145423A1 (en) * 2006-12-14 2008-06-19 Ajmal Ali Khan Chewable tablet and method of formulating
WO2009027786A2 (en) * 2007-08-29 2009-03-05 Pfizer Inc. Matrix dosage forms of varenicline
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
EP2262475A1 (en) * 2008-04-01 2010-12-22 Schering-Plough Healthcare Products, Inc. Chewable tablet and method of formulating
US8039620B2 (en) 2008-05-22 2011-10-18 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2432437A4 (en) * 2009-05-21 2012-12-19 Bionex Pharmaceuticals Llc TWO- AND ONE-LAYER DOSAGE FORMS
US8178537B2 (en) 2009-06-22 2012-05-15 Teva Pharmaceutical Industries Ltd. Solid state forms of varenicline salts and processes for preparation thereof
EP3485878A1 (en) 2010-09-01 2019-05-22 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management
CN102183182A (zh) * 2011-03-27 2011-09-14 雷鸣 一种烟花纸筒整形方法
JP5925381B2 (ja) 2012-04-13 2016-05-25 ▲連雲▼港金康和信▲薬業▼有限公司Ｌｉａｎｙｕｎｇａｎｇ Ｊｉｎｋａｎｇ Ｈｅｘｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 化合物［４−（２−アミノ−１０−メチル−４−オキソ−６，７，８，９−テトラヒドロ−４ａ，７−エピミノピリミド［４，５−ｂ］［１，４］ジアゼピン−５（４Ｈ）−イル）ベンゾイル］−グルタメート及びその製造
KR20140087846A (ko) * 2012-12-31 2014-07-09 주식회사 삼양바이오팜 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법
KR20170038039A (ko) * 2014-07-30 2017-04-05 메르크 파텐트 게엠베하 분상, 직접 압축성 유형의 폴리비닐 알코올
WO2017119801A1 (ko) * 2016-01-08 2017-07-13 주식회사 씨티씨바이오 바레니클린 또는 이의 약학적으로 허용가능한 염을 함유하는 맛 차폐된 구강 투여용 약학 제제
KR102463733B1 (ko) 2017-06-30 2022-11-04 한미약품 주식회사 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물
EP4035660A1 (en) 2017-10-17 2022-08-03 Synthon B.V. Tablets comprising tamsulosin and solifenacin
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
KR20200034293A (ko) 2018-09-21 2020-03-31 한미약품 주식회사 제어 방출용 바레니클린 제제
CN115666546A (zh) * 2020-04-03 2023-01-31 卢普奥克西治疗公司 肠内有氧化疗法
CN118284405A (zh) 2021-09-29 2024-07-02 卢普奥克西治疗公司 肠有氧疗法
EP4452236A2 (en) 2021-12-23 2024-10-30 Medichem, S.A. Solid pharmaceutical formulations of varenicline

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8616669D0 (en) 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
JPH0816066B2 (ja) * 1986-07-18 1996-02-21 エーザイ株式会社 持続性薬効製剤
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
SE8803822D0 (sv) 1988-10-26 1988-10-26 Novel dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
JP3084729B2 (ja) * 1990-06-15 2000-09-04 横河電機株式会社 デジタルオシロスコープ
EP0553777B1 (en) 1992-01-29 2002-04-24 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
US5698224A (en) 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
RU2066196C1 (ru) * 1995-06-01 1996-09-10 Андрей Борисович Рейзин Средство "антиник" для облегчения отвыкания от табакокурения и лечения хронических бронхолегочных заболеваний курильщиков
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
US6605610B1 (en) 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
PT1044189E (pt) 1997-12-31 2008-04-22 Pfizer Prod Inc Compostos azapolicíclicos condensados com arilo
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
JP2003513033A (ja) * 1999-10-29 2003-04-08 メルク エンド カムパニー インコーポレーテッド 浸透圧制御放出薬剤送達装置
US6306436B1 (en) * 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
US20030175349A1 (en) 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
EP1390366B1 (en) * 2001-05-14 2005-08-31 Pfizer Products Inc. The citrate salt of 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene
EE05441B1 (et) * 2001-05-14 2011-08-15 Pfizer Products Inc. 5,8,14-triasatetratsklo[10,3,1,0 2,11,04,9]heksadeka-2(11),3,5,7,9-pentaeeni tartraatsoolad
MXPA04003807A (es) 2001-11-30 2004-07-30 Pfizer Prod Inc Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno.
EP1633358A1 (en) 2003-05-20 2006-03-15 Pfizer Products Inc. Pharmaceutical compositions of varenicline
WO2006040680A1 (en) 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
CN101420939A (zh) 2006-04-24 2009-04-29 辉瑞产品公司 用于药物递送装置的不对称膜

Also Published As

Publication number Publication date
CA2467490C (en) 2007-01-09
US20030180360A1 (en) 2003-09-25
PE20040121A1 (es) 2004-03-22
US7771748B2 (en) 2010-08-10
DE60218885T2 (de) 2008-01-17
JP2009108064A (ja) 2009-05-21
CN1596128A (zh) 2005-03-16
NO20042739L (no) 2004-07-23
PY0228832A (es) 2004-06-01
ES2282492T3 (es) 2007-10-16
RU2005135958A (ru) 2007-06-10
TW200300684A (en) 2003-06-16
MY130619A (en) 2007-07-31
RU2004116343A (ru) 2005-03-27
SV2004001418A (es) 2004-05-07
EP1448235B1 (en) 2007-03-14
PA8559501A1 (es) 2003-06-30
WO2003045437A8 (en) 2003-08-14
RU2314810C2 (ru) 2008-01-20
AU2002351008A1 (en) 2003-06-10
CN1864663A (zh) 2006-11-22
RU2272629C2 (ru) 2006-03-27
GT200200247A (es) 2003-06-25
CA2467490A1 (en) 2003-06-05
EP1448235A1 (en) 2004-08-25
ATE356625T1 (de) 2007-04-15
AU2002351008B2 (en) 2007-07-12
BR0214806A (pt) 2004-09-14
JP2005528330A (ja) 2005-09-22
KR20040063975A (ko) 2004-07-15
TWI327471B (en) 2010-07-21
DK1448235T3 (da) 2007-07-02
NZ532435A (en) 2005-04-29
PL208080B1 (pl) 2011-03-31
KR100892517B1 (ko) 2009-04-10
MXPA04003807A (es) 2004-07-30
IL161857A0 (en) 2005-11-20
UY27553A1 (es) 2003-06-30
ZA200403068B (en) 2005-04-22
PL370913A1 (pl) 2005-05-30
SI1448235T1 (sl) 2007-08-31
DE60218885D1 (de) 2007-04-26
PT1448235E (pt) 2007-05-31
WO2003045437A1 (en) 2003-06-05
KR20060125925A (ko) 2006-12-06

Similar Documents

Publication Publication Date Title
MXPA04003807A (es) Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno.
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
DK1257254T3 (da) Formuleringer indeholdende et anticholinergt lægemiddel til behandling af kronisk obstruktiv lungesygdom
SE0102276D0 (sv) Device and method for the administration of a medicament
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
AR037629A1 (es) Formulaciones farmaceuticas que comprenden un derivado de platino
AR033444A1 (es) Forma solida de dosificacion util para la administracion oral de un compuesto activo de nicotina, a traves de la mucosa y uso de un compuesto activo de nicotina para prepararla
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
AR033688A1 (es) Composicion parenteral reconstituible
DK0781281T3 (da) Beta-Carbolinderivater som melatonin-agonister, fremgangsmåder til fremstilling deraf og deres anvendelse som lægemiddel
AR018166A1 (es) Productos utilizables en el tratamiento de tumores, una composicion farmaceutica y el uso de una antraciclina sola o con un inhibidor de topoisomerasa iantineoplasico en la preparacion de medicamentos
AR036640A1 (es) Formulaciones y uso de las mismas
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
AR022621A1 (es) Composicion farmaceutica que contiene desoxipeganina para el tratamiento de la dependencia de la nicotina
AR087240A2 (es) Composiciones farmaceuticas que tienen epinastina y pseudoefedrina
UY25510A1 (es) Procedimiento para la producción de preparados efervescentes
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
DE60103276D1 (de) Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
NO20054417L (no) Fremgangsmate for fremstilling av farmasoytiske preperater i form av fibratholdige tabletter og de derved fremstilte tabletter

Legal Events

Date Code Title Description
FC Refusal